Dr. Benjamin C. Creelan, MD, MS

Dr. Creelan practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Creelan's NPI, 1326257262, was assigned on May 21, 2007. Dr. Creelan graduated from Sidney Kimmel Medical College in 2007. Dr. Creelan holds Florida license ME105675.

Dr. Creelan's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Creelan's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Creelan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Creelan practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Creelan's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Creelan is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Creelan's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists breast cancer, chronic leukemia, lung cancer and prostate cancer among the conditions Dr. Creelan treats.

CMS data shows 224 Medicare services from Dr. Creelan across 3 procedure codes in 2024, for 117 Medicare patients. Medicare paid $17,901 for them.

CMS counts 117 Medicare patients who saw Dr. Creelan in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Creelan's median patient age at 72, with 57% women.

In 2024, Dr. Creelan wrote 738 Medicare Part D claims for 114 patients. 70% of them were for generic drugs. CMS names the drug for 529 of them, across 21 drugs with 11 or more claims each, at $3,427,379 in total drug cost. In 2023, CMS named 446 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Creelan for performance year 2024, reported as part of a group. Dr. Creelan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Creelan as offering telehealth.

Dmand AI links 50 papers to Dr. Creelan, published from 2013 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Creelan has published most often in Clin Cancer Res. Dr. Creelan's most frequent co-authors are Scott Joseph Antonia, MD, Eric Haura, MD and Alberto A. Chiappori, MD.

Dmand AI links Dr. Creelan to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic.

CMS Open Payments shows 377 general payments to Dr. Creelan from 22 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. AstraZeneca Pharmaceuticals LP paid the most, $145,978. It also lists 4 research payments totaling $2,078 from 2018 to 2020.

Dr. Creelan graduated from Sidney Kimmel Medical College in 2007.

Dr. Creelan is in network with 9 carriers, including Excellus BlueCross BlueShield, Elevance and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.